Enhabit, INC DEF 14A proxy statements

Enhabit, Inc. announces an agreement to be acquired by Kinderhook Industries, aiming to leverage new resources as a private company.

Enhabit, Inc. announced an agreement to be acquired by private investment firm Kinderhook Industries, transitioning to a privately held company.

Enhabit, Inc. announces its acquisition by private equity firm Kinderhook Industries for $13.80 per share in cash.

Enhabit, Inc., a national home health and hospice provider, has agreed to be acquired by Kinderhook Industries, LLC in an all-cash transaction valued at approximately $1.1 billion, with stockholders receiving $13.80 per share.

Enhabit, Inc. has filed a definitive proxy statement with the SEC, providing information for shareholders regarding upcoming decisions.

Enhabit, Inc. is set to hold its 2025 Annual Meeting of Stockholders on June 26, 2025, featuring proposals for director elections, auditor ratification, executive compensation, and equity incentive plan approval.

Enhabit, Inc. announced the preliminary vote count from its 2024 Annual Meeting of Stockholders, indicating the election of eight of its director nominees and one nominee proposed by AREX Capital Management, LP.

Enhabit is urging stockholders to vote for its nominees at the upcoming annual meeting on July 25, highlighting recent operational improvements and warning against the alternative slate proposed by AREX.

Enhabit is urging stockholders to vote for its nine director nominees on the YELLOW proxy card, highlighting recent strong operational results and progress in driving value creation amidst a takeover attempt by AREX Capital Management.

Enhabit, Inc. released unaudited preliminary results for Q2 2024, indicating business stabilization and progress in key operational areas.

Institutional Shareholder Services (ISS) recommends Enhabit stockholders vote FOR a majority of the company's director nominees, acknowledging recent promising performance and building momentum.

Enhabit, Inc. announces a 6.4% year-over-year increase in home health admissions and a fifth consecutive month of sequential census growth for hospice in Q2 2024.

Enhabit is urging stockholders to vote for its director nominees at the upcoming 2024 Annual Meeting, arguing that AREX Capital Management's proposed board members lack relevant experience and their transformation committee would be disruptive.

Enhabit, Inc. announced the posting of a new investor relations presentation on its website on July 1, 2024.

Enhabit urges stockholders to vote for its director nominees, highlighting recent performance improvements and strategic initiatives in response to a proxy contest by AREX Capital Management.

Enhabit, Inc. addresses misstatements by AREX Capital Management, defending its progress in stabilizing the business and urging stockholders to vote for its director nominees.

Enhabit's management team provided updates on their strategic priorities, payer innovation initiatives, and growth outlook at recent healthcare conferences.

Enhabit, Inc. communicated with its employees on June 17, 2024, regarding the proxy statement.

Enhabit, Inc. has filed a definitive proxy statement with the SEC, providing information for shareholders regarding upcoming decisions.

AREX Capital, a significant Enhabit stockholder, is soliciting proxies to elect its seven nominees to the board, aiming to address what it perceives as the company's underperformance and strategic missteps.

Enhabit's CEO and CFO will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on June 11th.

Enhabit files definitive proxy materials and urges stockholders to vote for its nine nominees on the YELLOW proxy card, highlighting decisive actions to stabilize the business and position the company for value creation.

Enhabit, Inc. is urging stockholders to vote for its slate of nine director nominees at the upcoming annual meeting, amidst a challenge from activist hedge fund AREX Capital Management, LP, which has nominated seven candidates.

Enhabit files preliminary proxy materials and provides additional details on its strategic review process, which concluded without any actionable proposals despite engaging with 38 potential counterparties.